Patient Resources | Otezla® (apremilast) for PsO
Indications
Approved Uses Otezla® (apremilast) is a prescription medicine used for the treatment of:
  • Adult patients with plaque psoriasis for whom phototherapy or systemic therapy is appropriate. Read more >
Approved Uses Otezla® (apremilast) is a prescription medicine used for the treatment of:
  • Adult patients with plaque psoriasis for whom phototherapy or systemic therapy is appropriate.
  • Pediatric patients 6 years of age and older and weighing at least 20 kg with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
  • Adult patients with active psoriatic arthritis.
  • Adult patients with oral ulcers associated with Behçet’s Disease. Read less >

Amgen® SupportPlus

Together,
we’ve got this.

When you’re prescribed Otezla,
you’re never alone.

We’re right here, right when you need us

Amgen® SupportPlus logo

Personalized patient support designed for you. With financial support resources and other helpful patient services, we are here to help you along the way.

  • Help with insurance questions
    Insurance coverage questions

    Amgen SupportPlus Representatives can help answer questions you may have regarding insurance coverage and can work with a specialty pharmacy to get your Otezla prescription.

  • $0 Co-Pay* Program
    Copay card

    If you have commercial insurance (usually self-purchased or through your job), you can get Otezla for $0* per month with the Otezla $0 Co-Pay Card.

    • Pay as little as $0* out-of-pocket for each dose
    • Can be applied to deductible, co-insurance, and co-payment*
    • No income eligibility requirement

    If your plan requires a pre-authorization or you are experiencing a delay in obtaining approval for Otezla, you can qualify for the Bridge to Commercial Coverage Offer and receive Otezla free for up to 12 prescription fills within 12 months while pursuing approval from your health plan. No purchase necessary. Please see full Terms and Conditions.

    *Eligibility criteria and program maximums apply. Please see the full Terms and Conditions.

  • Financial support resource for the uninsured or underinsured
    Financial support

    If you are uninsured or underinsured, Amgen® Safety Net Foundation is a nonprofit patient assistance program sponsored by Amgen® that helps qualifying patients access Amgen medicines at no cost. Click here to learn more.

  • Personalized support from an Amgen® Nurse Partner
    Amgen® Nurse partner

    With Otezla, you don’t have to do it alone. Dedicated Amgen Nurse Partners will be with you along the way to offer supplemental support and provide information about resources to help you access your prescribed Amgen medication. If you have any questions or concerns, you can call 1-844-4OTEZLA (1-844-468-3952) 8AM – 8PM ET, Monday – Friday.

    Amgen Nurse Partners are only available to patients that are prescribed certain Amgen products. They are not part of your treatment team and do not provide medical advice, nursing, or case management services. Amgen Nurse Partners will not inject patients with Amgen medications. Patients should always consult their healthcare provider regarding medical decisions or treatment concerns.

  • Resources and ongoing support
    Resources

    Access to helpful tools, resources, and more that you’ll need to get started with Otezla—plus more information on the approved uses and what the experts say about Otezla.

*Eligibility criteria and program maximums apply. See AmgenSupportPlus.com/copay-terms for full Terms and Conditions.

Interested in Amgen SupportPlus?

Get Otezla in 3 steps

Take a look at the Otezla Roadmap for information on getting your prescription.

DOWNLOAD
how is your treatement treating you

How’s your treatment treating you?

Your doctor wants to know how you’re feeling.

Pay as little as $0*

Did you know you may be eligible to pay as little as $0 per month through the Otezla Co-Pay Program? For eligible, commercially insured patients, your co-pay can be applied to deductible, co-insurance, and co-payment,* and is available regardless of your income level.

First-time co-pay card user? Find out more about how it works, and how it can help.

No insurance? Learn about other ways to access Otezla.

*For commercially insured patients only. Eligibility criteria and program maximums apply.
See AmgenSupportPlus.com/copay-terms for full Terms and Conditions.
Caregivers of kids and teens under 18 can contact Amgen® SupportPlus at
1-844-4OTEZLA (1-844-468-3952) to complete enrollment, Monday – Friday, 8 AM – 8 PM ET.
Hand holding copay card from Amgen® SupportPlus program
Hand holding copay card from Amgen® SupportPlus program
Man working on his laptop

Sign up now

Want to get Otezla information in your inbox? Sign up for emails.

IMPORTANT SAFETY INFORMATION

You must not take Otezla if you are allergic to apremilast or to any of the ingredients in Otezla.

Otezla can cause allergic reactions, sometimes severe. Stop using Otezla and call your healthcare provider or seek emergency help right away if you develop any of the following symptoms of a serious allergic reaction: trouble breathing or swallowing, raised bumps (hives), rash or itching, swelling of the face, lips, tongue, throat or arms.

Otezla can cause severe diarrhea, nausea, and vomiting, especially within the first few weeks of treatment. Use in elderly patients and the use of certain medications with Otezla appears to increase the risk of complications from having severe diarrhea, nausea, or vomiting. Tell your doctor if any of these conditions occur.

Otezla is associated with an increase in depression. In clinical studies, some patients reported depression, or suicidal behavior while taking Otezla. Some patients stopped taking Otezla due to depression. Before starting Otezla, tell your doctor if you have had feelings of depression, or suicidal thoughts or behavior. Be sure to tell your doctor if any of these symptoms or other mood changes develop or worsen during treatment with Otezla.

Some patients taking Otezla lost body weight. Your doctor should monitor your weight regularly. If unexplained or significant weight loss occurs, your doctor will decide if you should continue taking Otezla. For children 6 years of age or older, their doctor should monitor their growth (height and weight). If they are not growing or gaining weight as expected, their doctor will decide if they should continue taking Otezla.

Some medicines may make Otezla less effective and should not be taken with Otezla. Tell your doctor about all the medicines you take, including prescription and nonprescription medicines.

The most common side effects of Otezla include diarrhea, nausea, upper respiratory tract infection, tension headache, and headache. These are not all the possible side effects with Otezla. Ask your doctor about other potential side effects. Tell your doctor about any side effect that bothers you or does not go away.

Tell your doctor if you are pregnant, planning to become pregnant or planning to breastfeed.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-332-1088.

Please click here for the Full Prescribing Information for Otezla.

APPROVED USES

Otezla® (apremilast) is a prescription medicine used for the treatment of:

  • Adult patients with plaque psoriasis for whom phototherapy or systemic therapy is appropriate.
  • Pediatric patients 6 years of age and older and weighing at least 20 kg with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
  • Adult patients with active psoriatic arthritis.
  • Adult patients with oral ulcers associated with Behçet’s Disease.

IMPORTANT SAFETY INFORMATION

You must not take Otezla if you are allergic to apremilast or to any of the ingredients in Otezla.

Otezla can cause allergic reactions, sometimes severe. Stop using Otezla and call your healthcare provider or seek emergency help right away if you develop any of the following symptoms of a serious allergic reaction: trouble breathing or swallowing,